Previous 10 | Next 10 |
Thinly traded nano cap Brickell Biotech (NASDAQ: BBI ) is up 118% premarket on increased volume in reaction to positive data from a Japan-based Phase 3 clinical trial evaluating lead candidate topical sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis ...
Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis All primary and secondary endpoints were met and achieved statistical significance BOULDER, Colo., June 15, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (...
Brickell Biotech, Inc. (BBI) Q1 2020 Earnings Conference Call May 13, 2020, 16:30 ET Company Participants Michael Carruthers - CFO Robert Brown - CEO & Director Conference Call Participants Patricia Bank - Westwicke Partners Presentation Operator Welcome, everyo...
Brickell Biotech (NASDAQ: BBI ): Q1 GAAP EPS of -$0.45. Revenue of $1.05M (-69.9% Y/Y). Cash and equivalents of $7.1M. Press Release More news on: Brickell Biotech, Inc., Earnings news and commentary, Healthcare stocks news, ,
BOULDER, Colo., May 13, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today anno...
BOULDER, Colo., May 04, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today anno...
Brickell Biotech, Inc. (BBI) Q4 2019 Results Conference Call March 18, 2020 04:30 PM ET Company Participants Patti Bank - MD, Westwicke Partners Rob Brown - CEO Mike Carruthers - CFO Andy Sklawer - Co-Founder and COO Adam levy - Chief Business Officer Conference Call Parti...
Brickell Biotech (NASDAQ: BBI ): Q4 GAAP EPS of -$1.38. More news on: Brickell Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
BOULDER, Colo., March 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today an...
BOULDER, Colo., March 09, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today an...
News, Short Squeeze, Breakout and More Instantly...
Brickell Biotech Inc. Company Name:
BBI Stock Symbol:
NYSE Market:
New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Compan...
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early precl...
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoi...